Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Mononitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | BCHE | P06276 | 6/20 | 0.58 |
| ▸ | GSR | P00390 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Mononitrate SCHEMBL8893635 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8894719 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL3056251 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL616518 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL5482432 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL23906861 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL12787633 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL26782 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL22067709 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8893344 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | MAPT 4304/4885ALDH1A1 204/4885BCHE 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.